){kind=logo}
){kind=logo}
Buying, Building or Partnering: The New Sourcing Model for Scientific Compute
Analyze how biopharma leaders are deciding when to own infrastructure, rely on hyperscalers or work with specialist compute partners.
Weigh the trade-offs across talent, speed, capital efficiency, resilience and long-term differentiation.
Define which capabilities should remain strategic in-house as scientific compute becomes more central to R&D advantage.